Broadwood Capital Inc Lineage Cell Therapeutics, Inc. Transaction History
Broadwood Capital Inc
- $1.29 Billion
- Q3 2024
A detailed history of Broadwood Capital Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Broadwood Capital Inc holds 41,666,255 shares of LCTX stock, worth $24.2 Million. This represents 2.94% of its overall portfolio holdings.
Number of Shares
41,666,255
Previous 41,666,255
-0.0%
Holding current value
$24.2 Million
Previous $41.7 Million
9.0%
% of portfolio
2.94%
Previous 3.19%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
121Shares Held
94.2MCall Options Held
63.8KPut Options Held
1K-
Black Rock Inc. New York, NY9.56MShares$5.54 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$4.99 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$2.9 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$2.9 Million0.6% of portfolio
-
Raffles Associates LP New York, NY4.51MShares$2.61 Million4.64% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $98.5M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...